NCT07619287 An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
| NCT ID | NCT07619287 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | BeOne Medicines |
| Condition | Myeloid Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 118 participants |
| Start Date | 2026-06-23 |
| Primary Completion | 2028-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 118 participants in total. It began in 2026-06-23 with a primary completion date of 2028-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
Eligibility Criteria
Inclusion Criteria: * Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF). * Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories: * Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable/inaccessible, or declined by patient. * Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Exclusion Criteria: * Prior exposure to KAT6A/B inhibitors/degraders. * A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia. * Known central nervous system involvement by leukemia * Use of antileukemic therapies without sufficient washout period Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Contact & Investigator
Study Director
STUDY DIRECTOR
BeOne Medicine
Frequently Asked Questions
Who can join the NCT07619287 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloid Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07619287 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07619287 currently recruiting?
Yes, NCT07619287 is actively recruiting participants. Contact the research team at clinicaltrials@beonemed.com for enrollment information.
Where is the NCT07619287 trial being conducted?
This trial is being conducted at Kurralta Park, Australia, Nedlands, Australia, Tianjin, China, Auckland, New Zealand.
Who is sponsoring the NCT07619287 clinical trial?
NCT07619287 is sponsored by BeOne Medicines. The principal investigator is Study Director at BeOne Medicine. The trial plans to enroll 118 participants.